摘要
新型抗肿瘤疗法大大提高了癌症的存活率; 然而,他们正在引入新形式的心肌病,这通常可以限制适当的癌症治疗。 因此,需要新的心脏保护疗法,以改善癌症患者的临床结果。 为了测试新的治疗策略,对化学疗法诱发的心肌病的适当实验模型的需求越来越多。 诱导的多能干细胞和人类胚胎干细胞(hESC)来源的心肌细胞可用作替代体外模型,用于研究化疗诱发型心肌病的机制。 在本综述中,我们讨论了使用iPS-和hESC衍生的心肌细胞来评估额外的药物靶点和预测化疗引起的心脏毒性。
关键词: 心脏干细胞,化疗诱导的心脏毒性,多能干细胞,临床前模型,心肌病,人类胚胎干细胞。
图形摘要
Current Drug Targets
Title:Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Volume: 18 Issue: 6
关键词: 心脏干细胞,化疗诱导的心脏毒性,多能干细胞,临床前模型,心肌病,人类胚胎干细胞。
摘要: Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Export Options
About this article
Cite this article as:
Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160401125404
DOI https://dx.doi.org/10.2174/1389450117666160401125404 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Diseases and Natural Products
Current Protein & Peptide Science microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Meet Our Editor:
Current Cardiology Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Triglyceride Level Affecting Shared Susceptibility Genes in Metabolic Syndrome and Coronary Artery Disease
Current Medicinal Chemistry Sudden Unexpected Death in Infancy and the Dilemma of Defining the Sudden Infant Death Syndrome
Current Pediatric Reviews Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Heart Failure Modulates the Muscle Reflex
Current Cardiology Reviews Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart
Current Gene Therapy Classification of Heart Disease Using MFO Based Neural Network on MRI Images
Current Medical Imaging Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions
Current Medicinal Chemistry The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews Mitochondria-Targeted Drugs
Current Molecular Pharmacology Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Editorial [News in Therapy of Cardiomyopathy (Executive Editor: Giovanni Fazio)]
Current Pharmaceutical Design Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design